3CAI

3CAI

Catalog Number:
L002370615APE
Mfr. No.:
APE-B4688
Price:
$180
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          Target: AktIC50: 1 μM3CAI is a potent allosteric and specific inhibitor of AKT, which directly binds with AKT1 or AKT2 in an ATP noncompetitive manner and shows 60% inhibition of AKT1 kinase activity at 1 μM [1]. The serine/threonine kinase AKT includes three members, AKT1, AKT2, and AKT3. AKT plays a critical role in promoting transformation and chemoresistance through inducing proliferation and inhibiting apoptosis. Therefore, AKT is regarded as a potential target for cancer therapy.In vitro: 3CAI (1 and 4 μM) significantly inhibited AKT1 kinase activity and decreased expression of AKT direct downstream targets including mTOR and GSK3β, respectively. 3CAI (4 μM) efficiently induced growth inhibition and apoptosis in HCT116 or HCT29 colon cancer cells [1].In vivo: 3CAI (30 mg/kg, oral administration) significantly suppressed colon cancer growth in an in vivo xenograft mouse model and inhibited the expression of AKT-target protein such as mTOR and GSK3βin HCT116 colon tumor tissues [1].

      • Properties
        • CAS Number
          28755-03-5
          Molecular Formula
          C10H8ClNO
          Molecular Weight
          193.63
          Purity
          98.21%
          Solubility
          insoluble in EtOH; insoluble in H2O; ≥6.8 mg/mL in DMSO
          Storage
          Store at -20°C

          * For Research Use Only

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.